Recursion Announces First Patient Dosed In Phase 1/2 Clinical Study Of REC-1245, A RBM39 Degrader For Biomarker-Enriched Solid Tumors And Lymphoma
Recursion Announces First Patient Dosed In Phase 1/2 Clinical Study Of REC-1245, A RBM39 Degrader For Biomarker-Enriched Solid Tumors And Lymphoma
- First program to result from end-to-end use of OS to identify a novel target and new chemical matter, which moved from target ID to IND enabling studies in under 18 months with ~200 compounds synthesized
- REC-1245 is a potent and selective RBM39 degrader with a potential first-in-class profile in Solid tumors and Lymphoma
- >100,000 patients in the US and EU5 initially addressable
- 第一個通過端到端使用操作系統來識別新靶標和新化學物質而得出的程序，該項目從靶標ID轉移到IND，可以在不到18個月的時間內合成約200種化合物的研究
- REC-1245 是一種強效的選擇性 RBM39 降解劑，在實體瘤和淋巴瘤中可能處於同類首創
- 美國和歐盟五國有超過 100,000 名患者最初可以接診
SALT LAKE CITY, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that the first patient has been dosed in its Phase 1/2 clinical trial of REC-1245, a new chemical entity for the treatment of biomarker-enriched solid tumors and lymphoma.
鹽湖城，2024年12月3日（GLOBE NEWSWIRE）——Recursion（納斯達克股票代碼：RXRX）是一家領先的臨床階段TechBio公司，致力於從根本上改善生活的生物學。該公司今天宣佈，在用於治療富含生物標誌物的實體瘤和淋巴瘤的新化學實體 REC-1245 的1/2期臨床試驗中，第一位患者已經服藥。
Recursion identified the novel regulatory role of RBM39 on CDK12 function using its AI-powered maps of biology. Recursion believes the modulation of RBM39 may be associated with a therapeutic effect in certain biomarker-enriched solid tumors and lymphoma. Preclinical data support that RBM39 degradation induces splicing defects which downregulate DNA Damage Response (DDR) networks and cell cycle checkpoints.
遞歸使用其人工智能驅動的生物學地圖確定了 RBM39 對 CDK12 功能的新調節作用。Recursion 認爲，RBM39 的調節可能與某些富含生物標誌物的實體瘤和淋巴瘤的治療效果有關。臨床前數據支持，RBM39 降解會誘發剪接缺陷，從而降低對 DNA 損傷響應 (DDR) 網絡和細胞週期檢查點的調節。
